| Literature DB >> 23585802 |
Masashi Maeda1, Naoya Kasahara, Junshi Doi, Yuki Iijima, Takeshi Kikuchi, Takumi Teratani, Eiji Kobayashi.
Abstract
OBJECTIVE: We developed a novel luciferase-based viability assay for assessing the viability of hearts preserved in different solutions. We examined whether this in vitro system could predict heart damage and survival after transplantation in rats.Entities:
Year: 2013 PMID: 23585802 PMCID: PMC3622429 DOI: 10.1136/heartasia-2012-010160
Source DB: PubMed Journal: Heart Asia ISSN: 1759-1104
Figure 1Preparation of luciferase transgenic (Luc-Tg) rat cardiac tissue chips for in vivo imaging. All preparation was done in a cold room. (A) Tissue chip-making system. (B) Several sizes of cardiac tissue chip (about 3–8 mm). (C) Cardiac tissue chip assay plate for in vivo imaging system and/or ELISA analysis. (D) Luc-Tg rat-derived cardiomyocyte viability, as measured by cellular ATP concentration and bioluminescence imaging using the in vivo imaging system. After photon count, cellular ATP extraction was measured.
Heart viability assessment
| Solution | 0 min | 10 min | 20 min | 30 min | 40 min | 50 min | 60 min | 70 min | 80 min |
|---|---|---|---|---|---|---|---|---|---|
| UW | 100±0 | 80.05±4.33c,d | 58.19±6.18c,d | 38.62±1.82c,d | 32.37±1.21c,d | 25.67±1.26c,d,e,f | 24.75±1.60c,d,e,f | 23.08±1.16c,d,e,f | 21.28±1.31c,d,e,f |
| ETK | 100±0 | 77.49±8.19c,d | 54.41±7.61b,c | 37.45±4.45c.d | 29.83±3.51c,d | 24.52±2.98c,d,e,f | 21.77±2.78c,d,e,f | 20.65±3.23c,d,e,f | 19.96±2.51c,d,e,f |
| HTK | 100±0 | 66.44±5.95 | 47.20±10.01a | 29.04±4.54a | 21.45±5.80 | 13.18±3.09 | 8.70±1.66 | 5.61±1.26b,c,d | 5.61±0.63c,d,e,f |
| EC | 100±0 | 74.50±3.35b,c | 48.07±1.94a | 39.44±2.44c,d | 28.44±2.18b,c | 23.88±1.82c,d,e,f | 20.87±1.10c,d,e,f | 15.65±1.24e | 15.64±1.09e |
| LR | 100±0 | 39.45±7.08 | 19.42±2.90 | 11.35±1.95 | 9.36±2.05 | 7.73±1.74 | 6.77±1.54 | 5.18±0.97 | 4.97±1.29 |
| Saline | 100±0 | 42.56±6.31 | 21.59±3.15 | 17.41±3.22 | 11.56±2.16 | 9.81±2.19 | 8.09±1.61 | 6.57±1.28 | 5.72±1.19 |
Bioluminescent imaging using the IVIS system assessed heart viability. All samples were exposed to organ preservation solutions and saline (control) at 4°C. Data are representative of seven independent experiments.
p Values estimated by repeated measure one-way analysis of variance (ANOVA) and one-way ANOVA were a: <0.05 for LR, b: <0.05 for saline, c: <0.01 for LR, d: <0.01 for saline, e: <0.05 for HTK and f: <0.01 for HTK.
EC, Euro-Collins; ETK, extracellular-trehalose-Kyoto solution; HTK, histidin-tryptophan-ketoglutarat solution; IVIS, in vivo imaging system; LR, lactated Ringer's; UW, University of Wisconsin.
Figure 2Cervical heart transplantation using the cuff technique after preservation of the heart in various different solutions at 4°C. (A) Cervical heart transplantation performed using the cuff technique. (B) Evaluation of the beating rate of preserved heart-grafts 24 h after transplantation. (C) Analysis of heart injury markers (CPK and lactase dehydrogenase (LDH)) in the sera of rats that had received preserved heart transplants. *<0.01 for solution, **<0.05 for solution by one-way analysis of variance. EC, Euro-Collins; ETK, extracellular-trehalose-Kyoto solution; HTK, histidin-tryptophan-ketoglutarat solution; UW, University of Wisconsin.
Figure 3Preserved heart-grafts were transplanted into the abdomen using conventional microsurgical suture techniques. (A) Macroscopic appearance of grafted hearts preserved for 1 h at 4°C. (B) Macroscopic appearance of heart-grafts 3 h after transplantation. (C) Macroscopic evaluation 3 h after transplantation of hearts that had been preserved for 1 h; imaging software was used (Adobe Photoshop; NIH web site, Scion Image). White bars, before transplantation; black bars, 3 h after transplantation (n=3 per solution; *p>0.05 and **p<0.05). (D) Morphological analysis by hematoxylin and eosin (HE) staining, apex area of transplanted hearts. (E) Atria area of transplanted hearts. Scale bars are 1 mm. (F) Immunostaining evaluation of damage in transplanted hearts. Analysis of zona occludens (ZO)-1 expression levels using diaminobenzidine (DAB) staining. (G) Combination image of myeloperoxidase (green) and 4',6-diamidino-2-phenylindole (DAPI) (blue) staining. (H) Apoptosis-positivity of cells, as shown by using caspase-3 antibody and DAB staining. All imaging photograph scale bars are 200 μm. EC, Euro-Collins; ETK, extracellular-trehalose-Kyoto solution; HTK, histidin-tryptophan-ketoglutarat solution; NS, normal saline; UW, University of Wisconsin.
Preserved heart conditions assessment
| UW | ETK | HTK | EC | Normal saline | |
|---|---|---|---|---|---|
| MPO | 4.231±1.423a,b,c | 10.612±2.743a,c,d | 52.754±12.531 | 46.112±8.951 | 63.028±13.742 |
| ZO-1 | 16.511±4.964 | 28.813±7.328a,e,c | 8.613±2.868 | 4.653±0.471 | 2.971±0.162 |
| Caspase-3 | 7.129±3.851c | 8.221±5.715c | 27.821±10.251 | 31.649±9.816 | 29.275±11.776 |
Measurement of immunostaining-positive cardiomyocytes in cold preserved at 1 h before transplanted 3 h. Data are representative of 10 random 200× fields per animal.
p Values estimated by repeated measure one-way ANOVA and one-way ANOVA were a: <0.01 for HTK, b: <0.05 for EC, c: <0.01 for saline, d: <0.05 for EC and e: <0.01 for EC.
EC, Euro-Collins; ETK, extracellular-trehalose-Kyoto solution; HTK, histidin-tryptophan-ketoglutarat solution; MPO, myeloperoxidase; UW, University of Wisconsin; ZO, zona occludens.